» Articles » PMID: 35163374

Role of Somatostatin Signalling in Neuroendocrine Tumours

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Feb 15
PMID 35163374
Authors
Affiliations
Soon will be listed here.
Abstract

Somatostatin (SST) is a small peptide that exerts inhibitory effects on a wide range of neuroendocrine cells. Due to the fact that somatostatin regulates cell growth and hormone secretion, somatostatin receptors (SSTRs) have become valuable targets for the treatment of different types of neuroendocrine tumours (NETs). NETs are a heterogeneous group of tumours that can develop in various parts of the body, including the digestive system, lungs, and pituitary. NETs are usually slow growing, but they are often diagnosed in advanced stages and can display aggressive behaviour. The mortality rate of NETs is not outstandingly increased compared to other malignant tumours, even in the metastatic setting. One of the intrinsic properties of NETs is the expression of SSTRs that serve as drug targets for SST analogues (SSAs), which can delay tumour progression and downregulate hormone overproduction. Additionally, in many NETs, it has been demonstrated that the SSTR expression level provides a prognostic value in predicting a therapeutic response. Furthermore, higher a SSTR expression correlates with a better survival rate in NET patients. In recent studies, other epigenetic regulators affecting SST signalling or SSA-mTOR inhibitor combination therapy in NETs have been considered as novel strategies for tumour control. In conclusion, SST signalling is a relevant regulator of NET functionality. Alongside classical SSA treatment regimens, future advanced therapies and treatment modalities are expected to improve the disease outcomes and overall health of NET patients.

Citing Articles

Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.

Kiesewetter B, Pfluger F, Melhorn P, Mazal P, Raderer M Clin Transl Oncol. 2024; .

PMID: 39316250 DOI: 10.1007/s12094-024-03732-w.


Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment.

Sozio S, Raynor W, Becker M, Yudd A, Kempf J EJNMMI Rep. 2024; 8(1):29.

PMID: 39266864 PMC: 11393224. DOI: 10.1186/s41824-024-00216-6.


An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.

Stefano E, Castro F, Ciccarese A, Muscella A, Marsigliante S, Benedetti M Int J Mol Sci. 2024; 25(16).

PMID: 39201255 PMC: 11354135. DOI: 10.3390/ijms25168568.


From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.

Melhorn P, Mazal P, Wolff L, Kretschmer-Chott E, Raderer M, Kiesewetter B Ther Adv Med Oncol. 2024; 16:17588359241240316.

PMID: 38529270 PMC: 10962050. DOI: 10.1177/17588359241240316.


Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989.

Al Musaimi O Cancers (Basel). 2024; 16(5).

PMID: 38473389 PMC: 11326481. DOI: 10.3390/cancers16051032.


References
1.
Fuentes-Fayos A, Garcia-Martinez A, Herrera-Martinez A, Jimenez-Vacas J, Vazquez-Borrego M, Castano J . Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. Minerva Endocrinol. 2019; 44(2):109-128. DOI: 10.23736/S0391-1977.19.02970-5. View

2.
Goo T, Akiba Y, Kaunitz J . Mechanisms of intragastric pH sensing. Curr Gastroenterol Rep. 2010; 12(6):465-70. PMC: 2974196. DOI: 10.1007/s11894-010-0147-7. View

3.
Sun L, Qian Q, Sun G, Mackey L, Fuselier J, Coy D . Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II. J Drug Target. 2015; 24(2):169-77. DOI: 10.3109/1061186X.2015.1066794. View

4.
Franck S, Gatto F, van der Lely A, Janssen J, Dallenga A, Nagtegaal A . Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. Neuroendocrinology. 2016; 105(1):44-53. PMC: 5475231. DOI: 10.1159/000448429. View

5.
Lee H, Suh M, Choi H, Ha S, Paeng J, Cheon G . A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. EJNMMI Res. 2020; 10(1):42. PMC: 7183516. DOI: 10.1186/s13550-020-00632-2. View